A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study.
Saved in:
| Title: | A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study. |
|---|---|
| Authors: | Ridha BH; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Crutch S; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Cutler D; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Frost C; London School of Hygiene and Tropical Medicine, University of London, London, UK., Knight W; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Barker S; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Epie N; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Warrington EK; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Kukkastenvehmas R; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Douglas J; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK., Rossor MN; Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK. m.rossor@ucl.ac.uk. |
| Source: | Alzheimer's research & therapy [Alzheimers Res Ther] 2018 May 01; Vol. 10 (1), pp. 44. Date of Electronic Publication: 2018 May 01. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
